Pharmacology bioRxiv
Sublingual buprenorphine film yields clinically relevant rat exposure
- Buprenorphine/naloxone sublingual film was given to unanesthetized male rats, a route closer to clinical use than earlier rodent methods.
- Plasma buprenorphine peaked within hours of a single dose and stayed measurable a day later, within a range described as therapeutic in patients.
- After three weeks of daily dosing, liver weight fell while serum liver enzymes and histology were unchanged.
Does matching plasma levels in a rat mean matching the clinic? Not by itself. Rats metabolize buprenorphine quickly, and the film's real value is bypassing first-pass loss, so active metabolite and naloxone exposure should be reported too. The lower liver weight without enzyme change also needs a vehicle-film control before anyone calls it benign.
Paper: bioRxiv ↗ Sublingual Buprenorphine/Naloxone Film in Unanesthetized Rats: Feasibility, Tolerability, and Plasma Exposure